- Home
- TR vs KNSA Comparison
TR vs KNSA Comparison
Compare TR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TR | KNSA |
|---|---|---|
| Founded | 1896 | 2015 |
| Country | United States | United Kingdom |
| Employees | 2100 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TR | KNSA |
|---|---|---|
| Price | $38.39 | $48.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $60.86 |
| AVG Volume (30 Days) | 143.2K | ★ 464.3K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ $32.36 | $182.33 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $32.70 | $26.27 |
| 52 Week High | $45.06 | $59.87 |
Technical Indicators
Market Signals| Indicator | TR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 40.53 |
| Support Level | $36.86 | $40.67 |
| Resistance Level | $43.20 | $49.57 |
| Average True Range (ATR) | 1.16 | 2.05 |
| MACD | -0.05 | -0.90 |
| Stochastic Oscillator | 37.85 | 21.73 |
Price Performance
Historical ComparisonAbout TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.